Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricNVONovo Nordisk A/SNVSNovartis AGAZNAstraZeneca PLC
Snapshot
Price$46.36$157.83$163.97
Market cap$210.12B$261.56B$284.73B
Valuation
P/E11.5x21.9x25.3x
Forward P/E9.8x20.1x18.9x
Growth
Revenue growth8.1%5.8%9.9%
EPS growth16.7%9.3%33.7%
Profitability
Net margin37.2%24.1%17.2%
ROE66.4%31.7%22.3%
Balance sheet & cash
Debt / equity0.67x0.77x0.61x
Free cash flow yield37.3%4.2%3.1%
Dividend yield3.6%2.9%1.7%
Verdict
Investment ratingStrong· 79Favorable· 67Favorable· 62

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearNVOtoday $46NVStoday $158AZNtoday $164
2027$40.59 – $59.53+28% CAGR$129.35 – $189.71+20% CAGR$164.43 – $241.17+47% CAGR
2028$47.38 – $69.49+22% CAGR$141.34 – $207.29+15% CAGR$219.86 – $322.47+40% CAGR
2029$55.30 – $81.11+20% CAGR$154.44 – $226.51+13% CAGR$293.98 – $431.17+38% CAGR
2030$64.56 – $94.68+20% CAGR$168.75 – $247.51+12% CAGR$393.08 – $576.52+37% CAGR
2031$75.36 – $110.52+19% CAGR$184.40 – $270.45+11% CAGR$525.59 – $770.86+36% CAGR
5-yr CAGR10.2% – 19.0%3.2% – 11.4%26.2% – 36.3%